|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Pravastatin#Drug Interactions]] |
| {{Pravastatin}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Drug Interactions==
| |
| | |
| ===Cyclosporine===
| |
| | |
| The risk of [[myopathy]]/[[rhabdomyolysis]]is increased with concomitant administration of [[Cyclosporine]]. Limit pravastatin to 20 mg once daily for concomitant use with [[Cyclosporine]] [see Dosage and Administration (2.5), Warnings and Precautions (5.1), and Clinical Pharmacology (12.3)].
| |
| | |
| ===Clarithromycin===
| |
| | |
| The risk of [[myopathy]]/[[rhabdomyolysis]]is increased with concomitant administration of [[Clarithromycin]]. Limit pravastatin to 40 mg once daily for concomitant use with [[Clarithromycin]] [see Dosage and Administration (2.6), Warnings and Precautions (5.1), and Clinical Pharmacology (12.3)].
| |
| | |
| | |
| ===Colchicine===
| |
| The risk of [[myopathy]]/[[rhabdomyolysis]] is increased with concomitant administration of [[colchicine]] [see Warnings and Precautions (5.1)].
| |
| | |
| ===Gemfibrozil===
| |
| | |
| Due to an increased risk of [[myopathy]]/[[rhabdomyolysis]]when HMG-CoA reductase inhibitors are coadministered with [[gemfibrozil]], concomitant administration of PRAVACHOL with [[gemfibrozil]] should be avoided [see Warnings and Precautions (5.1)].
| |
| | |
| ===Other Fibrates===
| |
| | |
| Because it is known that the risk of [[myopathy]] during treatment with HMG-CoA reductase inhibitors is increased with concurrent administration of other [[fibrates]], PRAVACHOL should be administered with caution when used concomitantly with other [[fibrates]] [see Warnings and Precautions (5.1)].
| |
| | |
| ===Niacin===
| |
| | |
| The risk of skeletal muscle effects may be enhanced when pravastatin is used in combination with [[niacin]]; a reduction in PRAVACHOL dosage should be considered in this setting [see Warnings and Precautions (5.1)].</div><ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PRAVACHOL (PRAVASTATIN SODIUM) TABLET [E.R. SQUIBB & SONS, L.L.C.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=897ad8b7-921d-eb02-a61c-3419e662a2da | publisher = | date = | accessdate = 18 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist|2}}
| |
| | |
| [[Category:Statins]]
| |
| [[Category:Bristol-Myers Squibb]]
| |
| [[Category:Diols]]
| |
| [[Category:Carboxylic acids]]</div>
| |
| [[Category:Carboxylate esters]]
| |
| [[Category:Naphthalenes]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |